The IPC Rapid Communications initiative aims to deliver concise, expert perspectives on emerging developments in psoriasis research, clinical practice, and health policy. Each publication highlights urgent or important issues where swift dissemination of expert insights can inform and improve patient care worldwide.
New discoveries, therapies, and data in psoriasis care evolve quickly—and clinicians need access to expert interpretation as soon as possible.
Rapid Communications allow IPC experts to respond to new evidence or pressing issues in real time, bridging the gap between guideline updates and helping practitioners stay current with global best practices.
Each Rapid Communication is a short, focused publication, typically under 500 words with up to five references, developed by IPC experts. Up to four are released annually and may take the form of expert commentaries, white papers, or position statements.
Selected manuscripts are fast-tracked for publication in peer-reviewed journals or shared on the IPC website to ensure timely global access.
Ideas are solicited annually from IPC members, Corporate Partners, and patient partner organizations. Submissions are evaluated by the IPC Editorial Committee based on:
Authors are chosen from among those who proposed the idea with attention to expertise and geographic diversity. While IPC aims to include idea contributors whenever possible, participation as an author is not guaranteed. Each manuscript undergoes a structured review and approval by the IPC Board of Directors before publication.
Stay up to date with the newest expert commentaries shaping psoriasis care.
Management of Moderate-to-Severe Psoriasis in Patients with Cancer: Guidance from the International Psoriasis Council. Gisondi P, Carrascosa JM, Jo SJ, et al. JAAD Reviews. Published online August 14, 2026. doi.org/10.1016/j.jdrv.2026.08.004.
Bridging Psoriasis and Metabolic Comorbidities: Toward Comprehensive Patient Management. Priorities from the International Psoriasis Council. Strober BE, Treichel AM, Bowcock AM, et al. J Am Acad Dermatol. Published online July 25, 2026. doi:10.1016/j.jaad.2026.07.066
International Psoriasis Council Psoriasis Disease Severity Reclassification: Update on Validity, Acceptance, and Implementation. Strober BE, Blauvelt A, van de Kerkhof PC, et al. J Am Acad Dermatol. 2025 Oct;93(4):1154-1157. doi: 10.1016/j.jaad.2025.05.1445. Epub 2025 Jun 6. PMID: 40484137.
These key clinical topics are under active development for upcoming Rapid Communication publications.
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
